Report
Olga Smolentseva

BIONTECH (BUY, TP USD135) | Safety concerns over adenoviral vaccines give boost to mRNA players

BIONTECH (BUY, TP USD135) | Safety concerns over adenoviral vaccines give boost to mRNA players
Underlying
BIONTECH

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Olga Smolentseva

Other Reports on these Companies
Other Reports from Bryan Garnier
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch